Kuros Biosciences AG (KURN) - Net Assets

Latest as of June 2026: CHF72.00 Million CHF ≈ $91.03 Million USD

Based on the latest financial reports, Kuros Biosciences AG (KURN) has net assets worth CHF72.00 Million CHF (≈ $91.03 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF120.15 Million ≈ $151.90 Million USD) and total liabilities (CHF48.15 Million ≈ $60.87 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kuros Biosciences AG (KURN) strategic investment index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CHF72.00 Million
% of Total Assets	59.93%
Annual Growth Rate	-0.86%
5-Year Change	-13.05%
10-Year Change	74.65%
Growth Volatility	1282.06

Kuros Biosciences AG - Net Assets Trend (2004–2025)

This chart illustrates how Kuros Biosciences AG's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see KURN market cap overview.

Annual Net Assets for Kuros Biosciences AG (2004–2025)

The table below shows the annual net assets of Kuros Biosciences AG from 2004 to 2025. Also explore KURN shareholders equity momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	CHF66.93 Million ≈ $84.62 Million	+13.93%
2024-12-31	CHF58.75 Million ≈ $74.27 Million	+3.59%
2023-12-31	CHF56.71 Million ≈ $71.70 Million	-17.64%
2022-12-31	CHF68.86 Million ≈ $87.06 Million	-10.54%
2021-12-31	CHF76.98 Million ≈ $97.32 Million	-9.01%
2020-12-31	CHF84.60 Million ≈ $106.96 Million	+8.66%
2019-12-31	CHF77.86 Million ≈ $98.43 Million	+1.79%
2018-12-31	CHF76.48 Million ≈ $96.70 Million	+4.57%
2017-12-31	CHF73.14 Million ≈ $92.47 Million	+90.86%
2016-12-31	CHF38.32 Million ≈ $48.45 Million	+5628.25%
2015-12-31	CHF669.00K ≈ $845.80K	+102.55%
2014-12-31	CHF-26.22 Million ≈ $-33.15 Million	-719.86%
2013-12-31	CHF4.23 Million ≈ $5.35 Million	-57.82%
2012-12-31	CHF10.03 Million ≈ $12.68 Million	+185.86%
2011-12-31	CHF-11.68 Million ≈ $-14.77 Million	-277.10%
2010-12-31	CHF6.59 Million ≈ $8.34 Million	-19.97%
2009-12-31	CHF8.24 Million ≈ $10.42 Million	-74.13%
2008-12-31	CHF31.86 Million ≈ $40.28 Million	-41.47%
2007-12-31	CHF54.43 Million ≈ $68.82 Million	+18.59%
2006-12-31	CHF45.90 Million ≈ $58.03 Million	-37.98%
2005-12-31	CHF74.01 Million ≈ $93.57 Million	-7.69%
2004-12-31	CHF80.17 Million ≈ $101.36 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Kuros Biosciences AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 5942645700.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	CHF2.56 Million	3.82%
Other Comprehensive Income	CHF41.33 Million	61.75%
Other Components	CHF52.98 Million	79.16%
Total Equity	CHF66.93 Million	100.00%

Kuros Biosciences AG Competitors by Market Cap

The table below lists competitors of Kuros Biosciences AG ranked by their market capitalization.

Company	Market Cap
Riley Exploration Permian Inc NYSE MKT:REPX	$721.17 Million
Tianjin Economic-technological Development Area Co Ltd SHE:000652	$721.18 Million
Shanghai Orient-Chip Technology Co. Ltd. A SHG:688061	$721.23 Million
Recticel BR:RECT	$721.75 Million
Amtran Technology Co Ltd TW:2489	$720.69 Million
Decai Decoration Co Ltd SHG:605287	$720.30 Million
Ceigall India NSE:CEIGALL	$720.14 Million
Nuh Cimento Sanayi AS IS:NUHCM	$719.98 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Kuros Biosciences AG's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 58,748,000 to 66,930,072, a change of 8,182,072 (13.9%).
Net income of 2,118,570 contributed positively to equity growth.
Share repurchases of 2,185,000 reduced equity.
New share issuances of 2,185,000 increased equity.
Other comprehensive income increased equity by 14,943,098.
Other factors decreased equity by 8,879,596.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CHF2.12 Million	+3.17%
Share Repurchases	CHF2.19 Million	-3.26%
Share Issuances	CHF2.19 Million	+3.26%
Other Comprehensive Income	CHF14.94 Million	+22.33%
Other Changes	CHF-8.88 Million	-13.27%
Total Change	CHF-	13.93%

Book Value vs Market Value Analysis

This analysis compares Kuros Biosciences AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 10.44x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 0.01x to 10.44x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-12-31	CHF1464.04	CHF16.88	x
2005-12-31	CHF1199.65	CHF16.88	x
2006-12-31	CHF720.67	CHF16.88	x
2007-12-31	CHF840.46	CHF16.88	x
2008-12-31	CHF488.78	CHF16.88	x
2009-12-31	CHF126.34	CHF16.88	x
2010-12-31	CHF101.09	CHF16.88	x
2011-12-31	CHF-179.01	CHF16.88	x
2012-12-31	CHF49.93	CHF16.88	x
2013-12-31	CHF14.63	CHF16.88	x
2014-12-31	CHF-74.52	CHF16.88	x
2015-12-31	CHF0.17	CHF16.88	x
2016-12-31	CHF6.19	CHF16.88	x
2017-12-31	CHF8.33	CHF16.88	x
2018-12-31	CHF7.47	CHF16.88	x
2019-12-31	CHF4.53	CHF16.88	x
2020-12-31	CHF3.48	CHF16.88	x
2021-12-31	CHF2.35	CHF16.88	x
2022-12-31	CHF2.03	CHF16.88	x
2023-12-31	CHF1.55	CHF16.88	x
2024-12-31	CHF1.58	CHF16.88	x
2025-12-31	CHF1.62	CHF16.88	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Kuros Biosciences AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.17%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.75%
• Asset Turnover: 1.13x
• Equity Multiplier: 1.60x
Recent ROE (3.17%) is above the historical average (-28.49%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	-29.75%	-580.01%	0.05x	1.10x	CHF-31.87 Million
2005	-38.48%	-653.51%	0.05x	1.11x	CHF-35.88 Million
2006	-75.28%	-4772.38%	0.01x	1.25x	CHF-39.14 Million
2007	-12.63%	-19.16%	0.29x	2.27x	CHF-12.32 Million
2008	-81.64%	-131.87%	0.18x	3.48x	CHF-29.20 Million
2009	-301.25%	-272.57%	0.13x	8.34x	CHF-25.65 Million
2010	-22.05%	-6.51%	0.41x	8.20x	CHF-2.11 Million
2011	0.00%	-1195.35%	0.05x	0.00x	CHF-17.61 Million
2012	-91.89%	-837.82%	0.04x	3.03x	CHF-10.22 Million
2013	-728.75%	-3082.60%	0.02x	9.57x	CHF-31.25 Million
2014	0.00%	-3402.60%	0.06x	0.00x	CHF-31.40 Million
2015	930.79%	97.99%	1.95x	4.87x	CHF6.16 Million
2016	-51.52%	-1860.89%	0.02x	1.14x	CHF-23.58 Million
2017	-22.54%	-3086.89%	0.01x	1.18x	CHF-23.80 Million
2018	-15.29%	-1635.38%	0.01x	1.12x	CHF-19.34 Million
2019	-14.45%	-439.36%	0.03x	1.13x	CHF-19.04 Million
2020	-13.62%	-285.22%	0.04x	1.12x	CHF-19.98 Million
2021	-9.80%	-54.59%	0.15x	1.19x	CHF-15.24 Million
2022	-21.20%	-81.15%	0.22x	1.20x	CHF-21.48 Million
2023	-24.20%	-40.90%	0.47x	1.26x	CHF-19.40 Million
2024	-6.33%	-4.92%	0.89x	1.44x	CHF-9.59 Million
2025	3.17%	1.75%	1.13x	1.60x	CHF-4.57 Million

Industry Comparison

This section compares Kuros Biosciences AG's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

Industry: Medical Devices
Average net assets among peers: $705,101,859
Average return on equity (ROE) among peers: 20.46%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Kuros Biosciences AG (KURN)	CHF72.00 Million	-29.75%	0.67x	$720.86 Million
Medartis Holding AG (MED)	$17.10 Million	19.38%	5.74x	$1.06 Billion
Medacta Group SA (MOVE)	$226.40 Million	22.76%	1.16x	$2.79 Billion
Sonova H Ag (SOON)	$1.87 Billion	19.23%	0.44x	$12.20 Billion

About Kuros Biosciences AG

SW:KURN Switzerland Medical Devices

Market Cap

$846.66 Million

CHF669.68 Million CHF

Market Cap Rank

#10404 Global

#129 in Switzerland

Share Price

CHF16.88

Change (1 day)

-5.38%

52-Week Range

CHF16.88 - CHF33.36

All Time High

CHF36.96